Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02384317 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02384317 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 7 participants.
The verdict
NCT02384317, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 in subjects with IgAN on background supportive therapy with a maximally tolerated dose of RAAS blockade. The primary efficacy objective is to evaluate the efficacy of CCX168 based on an improvement in proteinuria.
Interventions
- DRUG CCX168
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-03-27 |
| Est. Completion | 2018-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02384317
The ClinicalTrials.gov registry entry for NCT02384317 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CCX168 is the first listed.
NCT02384317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02384317 about?
NCT02384317 is a clinical study titled "Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade". The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 in subjects with IgAN on background supportive therapy with a maximally tolerated dose of RAAS blockade. The primary efficacy objective is to evaluate the efficacy of CCX168 based on an improvement in pro...
What is the current status of trial NCT02384317?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2015-03-27. Estimated completion is 2018-06-01.
What interventions are being tested in trial NCT02384317?
The interventions under investigation include: CCX168 (DRUG).
Who is sponsoring clinical trial NCT02384317?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.